<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01328379</url>
  </required_header>
  <id_info>
    <org_study_id>DER-401</org_study_id>
    <nct_id>NCT01328379</nct_id>
  </id_info>
  <brief_title>Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis</brief_title>
  <official_title>Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Two Doses of Oral Dalfampridine Extended Release Tablets (5 mg and 10 mg Twice Daily) in Patients With Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acorda Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acorda Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and efficacy of a lower dose of
      dalfampridine extended release tablets compared to the currently approved dose in improving
      walking in Multiple Sclerosis (MS) patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current study is designed as a prospective placebo-controlled trial to investigate the
      safety and efficacy of a lower dose of dalfampridine extended release tablets (5 mg twice
      daily) compared to the approved commercial dose of 10 mg twice daily in improving walking in
      MS patients during a four-week period of treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Walking Speed Near Maximum Plasma Concentration at Steady State (CmaxSS) of Placebo and Dalfampridine-ER (5mg and 10mg), Using the Timed 25 Foot Walk (T25FW).</measure>
    <time_frame>Baseline Visit 1 (double-blind study day 1) and approximately 3-4 hours post dose at Visit 3 (end of double-blind week 4)</time_frame>
    <description>The T25FW test is a quantitative measure of ambulatory function that is widely used by MS specialists to assess the global impact of the disease and its progression on the patient's physical disability.
A patient will stand with the toes of his/her shoes on the starting line (identified by a taped mark on the floor) and timing will begin when any part of the patient's foot crosses the tape. Timing will end when any part of the patient's foot crosses the finish line (identified by a taped mark on the floor). Time will be recorded in seconds and rounded to the nearest tenth of a second using a stopwatch provided for this study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Walking Speed Near Minimum Plasma Concentration at Steady State (CminSS) of Placebo, Dalfampridine-ER (5mg and 10mg), Using the Timed 25 Foot Walk (T25FW).</measure>
    <time_frame>Baseline Visit 1 (double-blind study day 1) and approximately 12 hours post dose at Visit 3 (end of double-blind week 4)</time_frame>
    <description>The T25FW test is a quantitative measure of ambulatory function that is widely used by MS specialists to assess the global impact of the disease and its progression on the patient's physical disability.
A patient will stand with the toes of his/her shoes on the starting line (identified by a taped mark on the floor) and timing will begin when any part of the patient's foot crosses the tape. Timing will end when any part of the patient's foot crosses the finish line (identified by a taped mark on the floor). Time will be recorded in seconds and rounded to the nearest tenth of a second using a stopwatch provided for this study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 12-item MS Walking Scale (MSWS-12) at Visit 3</measure>
    <time_frame>Baseline Visit 1 (double-blind study day 1) and Visit 3 (end of double-blind week 4)</time_frame>
    <description>The MSWS-12 is a multi-item rating scale that asks patients to rate limitations of their mobility due to MS during the preceding two weeks on a 5-point scale (from 1= not at all to 5=extremely). The scale assesses a range of activities of daily life that rely on walking, such as climbing stairs, moving around the home and walking distances outdoors. The MSWS-12 also addresses the quality of walking, with questions on the smoothness, speed, distance, effort, and mental concentration involved in walking, as well as the need for assistive devices.
For each visit, the MSWS-12 score was calculated by summing the 12 components and transforming into a scale with a range of 0 to 100.
MSWS-12 Score = 100 * [(Sum of Items 1-12) - 12]/48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in MSWS-12 at Visit 2</measure>
    <time_frame>Visit 1 (Baseline) and Visit 2 (start of third week double-blind treatment period )</time_frame>
    <description>The MSWS-12 is a multi-item rating scale that asks patients to rate limitations of their mobility due to MS during the preceding two weeks on a 5-point scale (from 1= not at all to 5=extremely). The scale assesses a range of activities of daily life that rely on walking, such as climbing stairs, moving around the home and walking distances outdoors. The MSWS-12 also addresses the quality of walking, with questions on the smoothness, speed, distance, effort, and mental concentration involved in walking, as well as the need for assistive devices.
For each visit, the MSWS-12 score was calculated by summing the 12 components and transforming into a scale with a range of 0 to 100.
MSWS-12 Score = 100 * [(Sum of Items 1-12) - 12]/48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Six-Minute Walk Distance at Visit 2</measure>
    <time_frame>Visit 1 (Baseline) and Visit 2 (start of third week double-blind treatment period )</time_frame>
    <description>The Six-Minute Walk, a test of endurance, measures the distance that a patient can walk in a period of 6 minutes. Six-minute walk distance will be reported in feet.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in EuroQol Group 5 Dimensions (EQ-5D) Scores at Visit 3.</measure>
    <time_frame>Baseline Visit 1 (double-blind study day 1) and Visit 3 (end of double-blind week 4)</time_frame>
    <description>Patients completed a brief, generic health status questionnaire: The five specific dimensional scores value patients' health related to mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. Each question has 3 distinguishable choices that can be analyzed using a 3-point scale (i.e. 1 = no problem, 2=some problems and 3= extreme problems).
A response of 1 indicates that the patient has no problem with the dimension tested and a response of 3 indicates that the patient has extreme problems with the dimension tested. For each visit, the average score of 5 dimensions was calculated by averaging the scores of 5 dimensions. EQ-5D final score ranges from 1-3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in EQ-5D Visual Analogue Self-rating (VAS) Score at Visit 3.</measure>
    <time_frame>Baseline Visit 1 (double-blind study day 1) and Visit 3 (end of double-blind week 4)</time_frame>
    <description>The EQ-5D is a brief questionnaire that asks patients to rate general state of health. The VAS score rates the general state of health of a patient with 100 for the best imaginable health state and 0 for the worst imaginable health state.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">430</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Dalfampridine-ER 5mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5mg, twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dalfampridine-ER 10mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10mg, twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo, twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dalfampridine-ER 5mg</intervention_name>
    <description>5mg, twice daily</description>
    <arm_group_label>Dalfampridine-ER 5mg</arm_group_label>
    <other_name>Fampridine, Dalfampridine, Ampyra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dalfampridine-ER 10mg</intervention_name>
    <description>10mg, twice daily</description>
    <arm_group_label>Dalfampridine-ER 10mg</arm_group_label>
    <other_name>Fampridine, Dalfampridine, Ampyra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo, twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has clinically definite Multiple Sclerosis as defined by the MacDonald
             Criteria.

          -  Patient must be 18 to 70 years of age, inclusive (i.e. on or after their 18th
             birthday, up to the day before their 71st birthday at the Screening Visit).

          -  Patient who has previously taken Ampyra® or dalfampridine (fampridine or 4
             aminopyridine; 4-AP) in any formulation (including compounded), must have withdrawn
             from the drug for at least one month prior to the Screening Visit.

          -  Patient must be mentally competent to understand and sign the Internal Review Board
             (IRB)-approved informed consent prior to the performance of any study-specific
             procedures.

          -  Patient is able to perform all the required study procedures.

          -  In the judgement of the Investigator, the patient has MS-related walking impairment
             but has sufficient ambulatory ability to be able to complete two trials of the Timed
             25 Foot Walk (T25FW) at the screening Visit and every study visit thereafter, with the
             two trials completed within 5 minutes of one another and in accordance with the
             specific instructions provided by the National Multiple Sclerosis Society MS
             Functional Composite Manual.

          -  Patient who is female and of childbearing potential (see Exclusion Criterion 1 for
             definition) must have a negative urine pregnancy test at the Screening Visit.

        Exclusion Criteria:

          -  Patient is a female of childbearing potential (i.e., has not had a hysterectomy or
             bilateral oophorectomy, or is not at least two years postmenopausal), engaged in
             active heterosexual relations and is not using one of the following birth control
             methods: tubal ligation, implantable contraception device, oral, patch or injectable
             contraceptive, double barrier method, or sexual activity restricted to vasectomized
             partner.

          -  Patient is pregnant or breastfeeding.

          -  Patient has any history of seizures.

          -  Patient has moderate or severe renal impairment as defined by a calculated creatinine
             clearance of ≤ 50 mL/minute.

          -  Patient has active urinary tract infection (UTI) at Screening or within the 4 weeks
             before Screening.

          -  Patient has had an onset (as assessed by the treating physician) of an MS exacerbation
             within 60 days prior to the Screening Visit.

          -  Patient has started on a concomitant prescription medication regimen within the last
             three weeks, and/or their concomitant medication regimen is expected to change during
             the course of the study.

          -  Patient has received cyclophosphamide (Cytoxan) or mitoxantrone (Novantrone) for MS
             treatment within six months prior to the Screening Visit.

          -  Patient has started a treatment regimen of Betaseron, Avonex, Copaxone, Rebif,
             Tysabri, Extavia or Gilenya™ within 90 days prior to the Screening Visit or has had
             any change in the dosing regimen of these drugs within 30 days prior to the Screening
             Visit.

          -  Patient has received corticosteroids (other than topical preparations) within 30 days
             prior to the Screening Visit and/or is expected to receive regularly scheduled
             corticosteroid treatment during the course of the study.

          -  Patient has been administered botulinum toxin in the lower extremities within six
             months prior to the Screening Visit and/or is expected to receive botulinum toxin in
             the lower extremities during the course of the study.

          -  Patient has a known allergy to pyridine-containing substances or any of the inactive
             ingredients of the dalfampridine tablet (colloidal silicon dioxide, hydroxypropyl
             methylcellulose, magnesium stearate, microcrystalline cellulose, polyethylene glycol,
             and titanium dioxide).

          -  Patient has a history of drug or alcohol abuse within the past year.

          -  Patient has clinically significant abnormal laboratory values.

          -  Patient has angina, uncontrolled hypertension, clinically significant cardiac
             arrhythmias, or any other clinically significant cardiovascular abnormality.

          -  Patient has any medical condition (including psychiatric disease)that would interfere
             with the interpretation of the study results or the conduct of the study.

          -  Patient has participated in an investigational trial 30 days prior to Screening Visit
             or plans to enroll in another investigational trial at any time during this study.
             Non-drug (i.e. observational, registry) and non- medical device trials are allowed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew R. Blight, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Acorda Therapeutics</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Agius, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Angela Applebee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Vermont Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>S. A Azizi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Temple University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francois Bethoux, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christopher Bever, Jr., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland, Maryland Center for Multiple Sclerosis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Borresen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Metrolina Medical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aaron Boster, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University, Columbus</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ann Camac, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lahey Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Cascione, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Axiom Clinical Research of Florida</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jane Chan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Veterans Administration Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Warren Chumley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associates in Neurology, PSC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joanna Cooper, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alta Bates Summit Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joy Derwenskus, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adam DiDio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Suncoast Neuroscience Associates, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dennis Dietrich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Advanced Neurology Specialists</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Geoffery Eubank, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neurological Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven Freedman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Raleigh Neurology Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel Giang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loma Linda University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lawrence Goldstick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neurology Specialists, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew Goodman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Gudesblatt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Comprehensive Multiple Sclerosis Care Center at South Shore Neurologic Associates, P.C.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barry Hendin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Phoenix Neurological Associates, LTD</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Craig Herrman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Josephson Wallack Munshower Neurology, PC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Honeycutt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neurology Associates, PA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruce Hughes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruan Neurology Clinical Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Samuel Hunter, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Advanced Neurosciences Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George Hutton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maxine Mesinger Multiple Sclerosis Clinic; Baylor College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dina Jacobs, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Todd Janus, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Iowa Health Des Moines</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Omar Khan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wayne State University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bhupendra Khatri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aurora Saint Luke's Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kiren Kresa-Reahl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charleston Area Medical Center Health Education and Research Institute, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christopher LaGanke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>North Central Neurology Associates, PC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sharon Lynch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Kansas Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michele Mass, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Mattson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Angeli Mayadev, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Swedish Neuroscience Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Donald Negroski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Negroski, Stein, Sutherland and Hanes Neurology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen Newman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Island Neurological Associates, PC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gabriel Pardo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mercy Multiple Sclerosis Center of Oklahoma Mercy Neuroscience Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>C. Fish Greenfield, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Neurology, PA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rekha Pillai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neurology Clinic, PC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>T. Hemanth Rao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Neurological Institute, PA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Syed Rizvi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rhode Island Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matthew Roller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Altru Health System Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Rossen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Springfield Neurology Associates, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alan Schulman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neurological Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James S Shafer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Multiple Sclerosis Center of Vero Beach</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jatin Shah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Arizona Neurological Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Sheremata, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami School of Medicine, Dept. of Neurology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brian Steingo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neurological Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Storey, Jr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Upstate Clinical Research, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ben Thrower, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shepherd Center, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlo Tornatore, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Georgetown University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>K A Lloyd, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hampton Roads Neurology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anthony Turel, Jr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Pennsylvania State University, Milton S. Hershey Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sibyl E Wray, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sibyl E. Wray, MD, Neurology, PC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel Wynn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Consultants in Neurology Ltd.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Yapundich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unifour Medical Research, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>North Central Neurology Associates, PC</name>
      <address>
        <city>Cullman</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phoenix Neurological Associates, Ltd</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Neurological Institute</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage Inc.</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sutter East Bay Physicians Medical Foundation</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuro-Pain Medical Center, Inc.</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Collaborative NeuroScience Network, Inc.</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Rehabilitation Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Associates, PA</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami School of Medicine, Dept. of Neurology</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurological Associates</name>
      <address>
        <city>Pompano Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologique Foundation, Inc.</name>
      <address>
        <city>Ponte Vedra</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suncoast Neuroscience Associates, Inc.</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Negroski, Sutherland and Hanes Neurology</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tallahassee Neurological Clinic, PA</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Axiom Clinical Research of Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Multiple Sclerosis Center of Vero Beach</name>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheperd Center, Inc.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultants in Neurology Ltd.</name>
      <address>
        <city>Northbrook</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Josephson Wallack Munshower Neurology, PC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Plaza Specialty</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruan Neurology Clinic and Research Center</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associates in Neurology, PSC</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland, Maryland Center for Multiple Sclerosis</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lahey Clinic</name>
      <address>
        <city>Lexington</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Springfield Neurology Associates, LLC</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Neurology Specialists</name>
      <address>
        <city>Great Falls</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Administration Sierra Neveda Health Care System</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Upstate Clinical Research, LLC</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center MS Comprehensive Care Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Multiple Sclerosis Care Center at South Shore Neurologic Associates</name>
      <address>
        <city>Patchogue</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Island Neurological Associates, PC</name>
      <address>
        <city>Plainview</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Charlotte</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Neurological Institute, PA</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Hickory, LLC</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raleigh Neurology Associates</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Winston-Salem</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altru Health System Clinic</name>
      <address>
        <city>Grand Forks</city>
        <state>North Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Ohio Neuroscience, LLC</name>
      <address>
        <city>Bellevue</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurological Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University, Columbus</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Specialists, Inc.</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OMRF Multiple Sclerosis Center of Excellence</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Multiple Sclerosis Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Pennsylvania State University, Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University School of Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Neurology Foundation, Inc.</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wesley Neurology Clinic, PC</name>
      <address>
        <city>Cordova</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Neurosciences Institute</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sibyl E. Wray, MD, Neurology, PC</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Neurology, PA</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kelsey-Seybold Clinic</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maxine Mesinger Multiple Sclerosis Clinic; Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fletcher Allen Health Care</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hampton Roads Neurology</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurological Associates</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Neuroscience Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora Saint Luke's Medical Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2011</study_first_submitted>
  <study_first_submitted_qc>April 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2011</study_first_posted>
  <results_first_submitted>April 16, 2013</results_first_submitted>
  <results_first_submitted_qc>July 11, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 13, 2013</results_first_posted>
  <last_update_submitted>September 3, 2013</last_update_submitted>
  <last_update_submitted_qc>September 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>4-Aminopyridine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were to be enrolled at a minimum of 60 investigational centers in the United States until a minimum of 405 patients had been randomized.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>placebo, twice daily</description>
        </group>
        <group group_id="P2">
          <title>Dalfampridine-ER 5mg</title>
          <description>5mg, twice daily
Dalfampridine-ER 5mg: 5mg, twice daily</description>
        </group>
        <group group_id="P3">
          <title>Dalfampridine-ER 10mg</title>
          <description>10mg, twice daily
Dalfampridine-ER 10mg: 10mg, twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="143"/>
                <participants group_id="P2" count="144"/>
                <participants group_id="P3" count="143"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="142"/>
                <participants group_id="P2" count="144"/>
                <participants group_id="P3" count="143"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Population: All randomized patients who took at least one dose of study medication.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>placebo, twice daily</description>
        </group>
        <group group_id="B2">
          <title>Dalfampridine-ER 5mg</title>
          <description>5mg, twice daily
Dalfampridine-ER 5mg: 5mg, twice daily</description>
        </group>
        <group group_id="B3">
          <title>Dalfampridine-ER 10mg</title>
          <description>10mg, twice daily
Dalfampridine-ER 10mg: 10mg, twice daily</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="142"/>
            <count group_id="B2" value="144"/>
            <count group_id="B3" value="143"/>
            <count group_id="B4" value="429"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.2" spread="0.83"/>
                    <measurement group_id="B2" value="52.2" spread="0.77"/>
                    <measurement group_id="B3" value="53.4" spread="0.79"/>
                    <measurement group_id="B4" value="52.6" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="98"/>
                    <measurement group_id="B4" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="132"/>
                    <measurement group_id="B2" value="137"/>
                    <measurement group_id="B3" value="140"/>
                    <measurement group_id="B4" value="409"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Walking Speed Near Maximum Plasma Concentration at Steady State (CmaxSS) of Placebo and Dalfampridine-ER (5mg and 10mg), Using the Timed 25 Foot Walk (T25FW).</title>
        <description>The T25FW test is a quantitative measure of ambulatory function that is widely used by MS specialists to assess the global impact of the disease and its progression on the patient’s physical disability.
A patient will stand with the toes of his/her shoes on the starting line (identified by a taped mark on the floor) and timing will begin when any part of the patient’s foot crosses the tape. Timing will end when any part of the patient’s foot crosses the finish line (identified by a taped mark on the floor). Time will be recorded in seconds and rounded to the nearest tenth of a second using a stopwatch provided for this study.</description>
        <time_frame>Baseline Visit 1 (double-blind study day 1) and approximately 3-4 hours post dose at Visit 3 (end of double-blind week 4)</time_frame>
        <population>Full Analysis Population (FAP): All randomized patients who took at least one dose of double-blind investigational medication and who have a baseline Timed 25 Foot Walk (T25FW) assessment and at least one post-baseline T25FW assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Dalfampridine-ER 5mg</title>
            <description>5mg, twice daily
Dalfampridine-ER 5mg: 5mg, twice daily</description>
          </group>
          <group group_id="O3">
            <title>Dalfampridine-ER 10mg</title>
            <description>10mg, twice daily
Dalfampridine-ER 10mg: 10mg, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Walking Speed Near Maximum Plasma Concentration at Steady State (CmaxSS) of Placebo and Dalfampridine-ER (5mg and 10mg), Using the Timed 25 Foot Walk (T25FW).</title>
          <description>The T25FW test is a quantitative measure of ambulatory function that is widely used by MS specialists to assess the global impact of the disease and its progression on the patient’s physical disability.
A patient will stand with the toes of his/her shoes on the starting line (identified by a taped mark on the floor) and timing will begin when any part of the patient’s foot crosses the tape. Timing will end when any part of the patient’s foot crosses the finish line (identified by a taped mark on the floor). Time will be recorded in seconds and rounded to the nearest tenth of a second using a stopwatch provided for this study.</description>
          <population>Full Analysis Population (FAP): All randomized patients who took at least one dose of double-blind investigational medication and who have a baseline Timed 25 Foot Walk (T25FW) assessment and at least one post-baseline T25FW assessment.</population>
          <units>feet per second</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="143"/>
                <count group_id="O3" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.363" spread="0.0511"/>
                    <measurement group_id="O2" value="0.423" spread="0.0470"/>
                    <measurement group_id="O3" value="0.478" spread="0.0569"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>dalfampridine-ER 5mg twice daily vs. placebo twice daily: Change from baseline in walking speed at Approximately CmaxSS at Visit 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.457</p_value>
            <p_value_desc>To demonstrate study sensitivity with respect to efficacy and maintain an overall alpha level ≤ 0.05, a stepwise procedure was performed.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA Model: Change from Baseline in Walking Speed - dependent variable and Baseline Walking Speed and Treatment - independent variables</method_desc>
            <param_type>least squares mean</param_type>
            <param_value>0.054</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0724</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.088</ci_lower_limit>
            <ci_upper_limit>0.196</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>dalfampridine-ER 10mg twice daily vs. placebo twice daily: Change from baseline in walking speed at Approximately CmaxSS at Visit 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.107</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA Model: Change from Baseline in Walking Speed - dependent variable and Baseline Walking Speed and Treatment - independent variables</method_desc>
            <param_type>least squares mean</param_type>
            <param_value>0.118</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0732</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.026</ci_lower_limit>
            <ci_upper_limit>0.262</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>dalfampridine-ER 5mg twice daily vs. dalfampridine-ER 10mg twice daily: Change from baseline in walking speed at Approximately CmaxSS at Visit 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.375</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA Model: Change from Baseline in Walking Speed - dependent variable and Baseline Walking Speed and Treatment - independent variables</method_desc>
            <param_type>least squares mean</param_type>
            <param_value>0.064</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0724</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.078</ci_lower_limit>
            <ci_upper_limit>0.207</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Walking Speed Near Minimum Plasma Concentration at Steady State (CminSS) of Placebo, Dalfampridine-ER (5mg and 10mg), Using the Timed 25 Foot Walk (T25FW).</title>
        <description>The T25FW test is a quantitative measure of ambulatory function that is widely used by MS specialists to assess the global impact of the disease and its progression on the patient’s physical disability.
A patient will stand with the toes of his/her shoes on the starting line (identified by a taped mark on the floor) and timing will begin when any part of the patient’s foot crosses the tape. Timing will end when any part of the patient’s foot crosses the finish line (identified by a taped mark on the floor). Time will be recorded in seconds and rounded to the nearest tenth of a second using a stopwatch provided for this study.</description>
        <time_frame>Baseline Visit 1 (double-blind study day 1) and approximately 12 hours post dose at Visit 3 (end of double-blind week 4)</time_frame>
        <population>Full Analysis Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Dalfampridine-ER 5mg</title>
            <description>5mg, twice daily
Dalfampridine-ER 5mg: 5mg, twice daily</description>
          </group>
          <group group_id="O3">
            <title>Dalfampridine-ER 10mg</title>
            <description>10mg, twice daily
Dalfampridine-ER 10mg: 10mg, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Walking Speed Near Minimum Plasma Concentration at Steady State (CminSS) of Placebo, Dalfampridine-ER (5mg and 10mg), Using the Timed 25 Foot Walk (T25FW).</title>
          <description>The T25FW test is a quantitative measure of ambulatory function that is widely used by MS specialists to assess the global impact of the disease and its progression on the patient’s physical disability.
A patient will stand with the toes of his/her shoes on the starting line (identified by a taped mark on the floor) and timing will begin when any part of the patient’s foot crosses the tape. Timing will end when any part of the patient’s foot crosses the finish line (identified by a taped mark on the floor). Time will be recorded in seconds and rounded to the nearest tenth of a second using a stopwatch provided for this study.</description>
          <population>Full Analysis Population</population>
          <units>feet per second</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="143"/>
                <count group_id="O3" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.301" spread="0.0496"/>
                    <measurement group_id="O2" value="0.296" spread="0.0429"/>
                    <measurement group_id="O3" value="0.391" spread="0.0513"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>dalfampridine-ER 5mg twice daily vs. placebo twice daily: Change from baseline in walking speed at Approximately CminSS at Visit 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.832</p_value>
            <p_value_desc>To demonstrate study sensitivity with respect to efficacy and maintain an overall alpha level ≤ 0.05, a stepwise procedure was performed.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA Model: Change from Baseline in Walking Speed - dependent variable and Baseline Walking Speed and Treatment - independent variables</method_desc>
            <param_type>Least Squares Mean</param_type>
            <param_value>-0.014</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0666</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.145</ci_lower_limit>
            <ci_upper_limit>0.117</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>dalfampridine-ER 10mg twice daily vs. placebo twice daily: Change from baseline in walking speed at Approximately CminSS at Visit 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.167</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA Model: Change from Baseline in Walking Speed - dependent variable and Baseline Walking Speed and Treatment - independent variables</method_desc>
            <param_type>Least Squares Mean</param_type>
            <param_value>0.093</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0674</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.039</ci_lower_limit>
            <ci_upper_limit>0.226</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>dalfampridine-ER 5mg twice daily vs. dalfampridine-ER 10mg twice daily: Change from baseline in walking speed at Approximately CminSS at Visit 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.108</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA Model: Change from Baseline in Walking Speed - dependent variable and Baseline Walking Speed and Treatment - independent variables</method_desc>
            <param_type>Least Squares Mean</param_type>
            <param_value>0.107</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0666</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.024</ci_lower_limit>
            <ci_upper_limit>0.238</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 12-item MS Walking Scale (MSWS-12) at Visit 3</title>
        <description>The MSWS-12 is a multi-item rating scale that asks patients to rate limitations of their mobility due to MS during the preceding two weeks on a 5-point scale (from 1= not at all to 5=extremely). The scale assesses a range of activities of daily life that rely on walking, such as climbing stairs, moving around the home and walking distances outdoors. The MSWS-12 also addresses the quality of walking, with questions on the smoothness, speed, distance, effort, and mental concentration involved in walking, as well as the need for assistive devices.
For each visit, the MSWS-12 score was calculated by summing the 12 components and transforming into a scale with a range of 0 to 100.
MSWS-12 Score = 100 * [(Sum of Items 1-12) – 12]/48</description>
        <time_frame>Baseline Visit 1 (double-blind study day 1) and Visit 3 (end of double-blind week 4)</time_frame>
        <population>Full Analysis Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Dalfampridine-ER 5mg</title>
            <description>5mg, twice daily
Dalfampridine-ER 5mg: 5mg, twice daily</description>
          </group>
          <group group_id="O3">
            <title>Dalfampridine-ER 10mg</title>
            <description>10mg, twice daily
Dalfampridine-ER 10mg: 10mg, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 12-item MS Walking Scale (MSWS-12) at Visit 3</title>
          <description>The MSWS-12 is a multi-item rating scale that asks patients to rate limitations of their mobility due to MS during the preceding two weeks on a 5-point scale (from 1= not at all to 5=extremely). The scale assesses a range of activities of daily life that rely on walking, such as climbing stairs, moving around the home and walking distances outdoors. The MSWS-12 also addresses the quality of walking, with questions on the smoothness, speed, distance, effort, and mental concentration involved in walking, as well as the need for assistive devices.
For each visit, the MSWS-12 score was calculated by summing the 12 components and transforming into a scale with a range of 0 to 100.
MSWS-12 Score = 100 * [(Sum of Items 1-12) – 12]/48</description>
          <population>Full Analysis Population</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="143"/>
                <count group_id="O3" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.35" spread="1.774"/>
                    <measurement group_id="O2" value="-9.73" spread="1.741"/>
                    <measurement group_id="O3" value="-11.10" spread="1.818"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>dalfampridine-ER 5mg twice daily vs. placebo twice daily: Change from baseline in MSWS-12 at visit 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.866</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA model with change from baseline in MSWS-12 Score as the dependent variable and baseline MSWS-12 Score and treatment as the independent variables</method_desc>
            <param_type>Lease Squares Mean</param_type>
            <param_value>-0.40</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.367</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.05</ci_lower_limit>
            <ci_upper_limit>4.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>dalfampridine-ER 10mg twice daily vs. placebo twice daily: Change from baseline in MSWS-12 at visit 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.286</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA model with change from baseline in MSWS-12 Score as the dependent variable and baseline MSWS-12 Score and treatment as the independent variables</method_desc>
            <param_type>Least Squares Mean</param_type>
            <param_value>-2.56</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.393</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.26</ci_lower_limit>
            <ci_upper_limit>2.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>dalfampridine-ER 5mg twice daily vs. dalfampridine-ER 10mg twice daily: Change from baseline in MSWS-12 at visit 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.362</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA model with change from baseline in MSWS-12 Score as the dependent variable and baseline MSWS-12 Score and treatment as the independent variables</method_desc>
            <param_type>Least Squares Mean</param_type>
            <param_value>-2.16</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.366</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.81</ci_lower_limit>
            <ci_upper_limit>2.49</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in MSWS-12 at Visit 2</title>
        <description>The MSWS-12 is a multi-item rating scale that asks patients to rate limitations of their mobility due to MS during the preceding two weeks on a 5-point scale (from 1= not at all to 5=extremely). The scale assesses a range of activities of daily life that rely on walking, such as climbing stairs, moving around the home and walking distances outdoors. The MSWS-12 also addresses the quality of walking, with questions on the smoothness, speed, distance, effort, and mental concentration involved in walking, as well as the need for assistive devices.
For each visit, the MSWS-12 score was calculated by summing the 12 components and transforming into a scale with a range of 0 to 100.
MSWS-12 Score = 100 * [(Sum of Items 1-12) – 12]/48</description>
        <time_frame>Visit 1 (Baseline) and Visit 2 (start of third week double-blind treatment period )</time_frame>
        <population>Full Analysis Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Dalfampridine-ER 5mg</title>
            <description>5mg, twice daily
Dalfampridine-ER 5mg: 5mg, twice daily</description>
          </group>
          <group group_id="O3">
            <title>Dalfampridine-ER 10mg</title>
            <description>10mg, twice daily
Dalfampridine-ER 10mg: 10mg, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in MSWS-12 at Visit 2</title>
          <description>The MSWS-12 is a multi-item rating scale that asks patients to rate limitations of their mobility due to MS during the preceding two weeks on a 5-point scale (from 1= not at all to 5=extremely). The scale assesses a range of activities of daily life that rely on walking, such as climbing stairs, moving around the home and walking distances outdoors. The MSWS-12 also addresses the quality of walking, with questions on the smoothness, speed, distance, effort, and mental concentration involved in walking, as well as the need for assistive devices.
For each visit, the MSWS-12 score was calculated by summing the 12 components and transforming into a scale with a range of 0 to 100.
MSWS-12 Score = 100 * [(Sum of Items 1-12) – 12]/48</description>
          <population>Full Analysis Population</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="142"/>
                <count group_id="O3" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.48" spread="1.713"/>
                    <measurement group_id="O2" value="-9.54" spread="1.526"/>
                    <measurement group_id="O3" value="-10.04" spread="1.817"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>dalfampridine-ER 5mg twice daily vs. placebo twice daily: Change from baseline in MSWS-12 at visit 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.708</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA model with change from baseline in MSWS-12 Score as the dependent variable and baseline MSWS-12 Score and treatment as the independent variables</method_desc>
            <param_type>Least Squares Mean</param_type>
            <param_value>0.84</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.237</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.56</ci_lower_limit>
            <ci_upper_limit>5.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>dalfampridine-ER 10mg twice daily vs. placebo twice daily: Change from baseline in MSWS-12 at visit 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.868</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA model with change from baseline in MSWS-12 Score as the dependent variable and baseline MSWS-12 Score and treatment as the independent variables</method_desc>
            <param_type>Least Squares Mean</param_type>
            <param_value>-0.38</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.258</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.81</ci_lower_limit>
            <ci_upper_limit>4.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>dalfampridine-ER 5mg twice daily vs. dalfampridine-ER 10mg twice daily: Change from baseline in MSWS-12 at visit 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.588</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA model with change from baseline in MSWS-12 Score as the dependent variable and baseline MSWS-12 Score and treatment as the independent variables</method_desc>
            <param_type>Least Squares Mean</param_type>
            <param_value>-1.21</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.236</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.61</ci_lower_limit>
            <ci_upper_limit>3.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Six-Minute Walk Distance at Visit 2</title>
        <description>The Six-Minute Walk, a test of endurance, measures the distance that a patient can walk in a period of 6 minutes. Six-minute walk distance will be reported in feet.</description>
        <time_frame>Visit 1 (Baseline) and Visit 2 (start of third week double-blind treatment period )</time_frame>
        <population>Full Analysis Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Dalfampridine-ER 5mg</title>
            <description>5mg, twice daily
Dalfampridine-ER 5mg: 5mg, twice daily</description>
          </group>
          <group group_id="O3">
            <title>Dalfampridine-ER 10mg</title>
            <description>10mg, twice daily
Dalfampridine-ER 10mg: 10mg, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Six-Minute Walk Distance at Visit 2</title>
          <description>The Six-Minute Walk, a test of endurance, measures the distance that a patient can walk in a period of 6 minutes. Six-minute walk distance will be reported in feet.</description>
          <population>Full Analysis Population</population>
          <units>Feet</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.7" spread="23.36"/>
                    <measurement group_id="O2" value="76.8" spread="27.31"/>
                    <measurement group_id="O3" value="128.6" spread="21.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>dalfampridine-ER 5mg twice daily vs. placebo twice daily: Change from baseline in Six-Minute Walk Distance at visit 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.308</p_value>
            <method>ANOVA</method>
            <method_desc>Change from Baseline in Six-Minute Walk Distance as dependent variable and Baseline Six-Minute Walk Distance and Treatment as independent variables.</method_desc>
            <param_type>Least Squares Mean</param_type>
            <param_value>35.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>34.57</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-33.0</ci_lower_limit>
            <ci_upper_limit>103.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>dalfampridine-ER 10mg twice daily vs. placebo twice daily: Change from baseline in Six-Minute Walk Distance at visit 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.014</p_value>
            <method>ANOVA</method>
            <method_desc>Change from Baseline in Six-Minute Walk Distance as dependent variable and Baseline Six-Minute Walk Distance and Treatment as independent variables.</method_desc>
            <param_type>Least Squares Mean</param_type>
            <param_value>87.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>34.90</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>18.2</ci_lower_limit>
            <ci_upper_limit>156.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>dalfampridine-ER 5mg twice daily vs. dalfampridine-ER 10mg twice daily: Change from baseline in Six-Minute Walk Distance at visit 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.133</p_value>
            <method>ANOVA</method>
            <method_desc>Change from Baseline in Six-Minute Walk Distance as dependent variable and Baseline Six-Minute Walk Distance and Treatment as independent variables.</method_desc>
            <param_type>Least Squares Mean</param_type>
            <param_value>51.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>34.21</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.9</ci_lower_limit>
            <ci_upper_limit>119.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in EuroQol Group 5 Dimensions (EQ-5D) Scores at Visit 3.</title>
        <description>Patients completed a brief, generic health status questionnaire: The five specific dimensional scores value patients’ health related to mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. Each question has 3 distinguishable choices that can be analyzed using a 3-point scale (i.e. 1 = no problem, 2=some problems and 3= extreme problems).
A response of 1 indicates that the patient has no problem with the dimension tested and a response of 3 indicates that the patient has extreme problems with the dimension tested. For each visit, the average score of 5 dimensions was calculated by averaging the scores of 5 dimensions. EQ-5D final score ranges from 1-3.</description>
        <time_frame>Baseline Visit 1 (double-blind study day 1) and Visit 3 (end of double-blind week 4)</time_frame>
        <population>Full Analysis Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Dalfampridine-ER 5mg</title>
            <description>5mg, twice daily
Dalfampridine-ER 5mg: 5mg, twice daily</description>
          </group>
          <group group_id="O3">
            <title>Dalfampridine-ER 10mg</title>
            <description>10mg, twice daily
Dalfampridine-ER 10mg: 10mg, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in EuroQol Group 5 Dimensions (EQ-5D) Scores at Visit 3.</title>
          <description>Patients completed a brief, generic health status questionnaire: The five specific dimensional scores value patients’ health related to mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. Each question has 3 distinguishable choices that can be analyzed using a 3-point scale (i.e. 1 = no problem, 2=some problems and 3= extreme problems).
A response of 1 indicates that the patient has no problem with the dimension tested and a response of 3 indicates that the patient has extreme problems with the dimension tested. For each visit, the average score of 5 dimensions was calculated by averaging the scores of 5 dimensions. EQ-5D final score ranges from 1-3.</description>
          <population>Full Analysis Population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="139"/>
                <count group_id="O3" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.023"/>
                    <measurement group_id="O2" value="-0.05" spread="0.020"/>
                    <measurement group_id="O3" value="-0.07" spread="0.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>dalfampridine-ER 5mg twice daily vs. placebo twice daily: Change from baseline in Average EQ-5D score at Visit 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.320</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA model with change from baseline score as the dependant variable and baseline score and treatment as the independent variables.</method_desc>
            <param_type>Least Squares Mean</param_type>
            <param_value>0.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.03</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>dalfampridine-ER 10mg twice daily vs. placebo twice daily: Change from baseline in Average EQ-5D score at Visit 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.734</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA model with change from baseline score as the dependant variable and baseline score and treatment as the independent variables.</method_desc>
            <param_type>Least Squares Mean</param_type>
            <param_value>-0.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.03</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1</ci_lower_limit>
            <ci_upper_limit>0.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>dalfampridine-ER 5mg twice daily vs. dalfampridine-ER 10mg twice daily: Change from baseline in Average EQ-5D score at Visit 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.185</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA model with change from baseline score as the dependant variable and baseline score and treatment as the independent variables.</method_desc>
            <param_type>Least Squares Mean</param_type>
            <param_value>-0.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.03</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1</ci_lower_limit>
            <ci_upper_limit>0.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in EQ-5D Visual Analogue Self-rating (VAS) Score at Visit 3.</title>
        <description>The EQ-5D is a brief questionnaire that asks patients to rate general state of health. The VAS score rates the general state of health of a patient with 100 for the best imaginable health state and 0 for the worst imaginable health state.</description>
        <time_frame>Baseline Visit 1 (double-blind study day 1) and Visit 3 (end of double-blind week 4)</time_frame>
        <population>Full Analysis Population. The number of participants analyzed corresponds with number of subjects who completed the questionnaire in each treatment group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Dalfampridine-ER 5mg</title>
            <description>5mg, twice daily
Dalfampridine-ER 5mg: 5mg, twice daily</description>
          </group>
          <group group_id="O3">
            <title>Dalfampridine-ER 10mg</title>
            <description>10mg, twice daily
Dalfampridine-ER 10mg: 10mg, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in EQ-5D Visual Analogue Self-rating (VAS) Score at Visit 3.</title>
          <description>The EQ-5D is a brief questionnaire that asks patients to rate general state of health. The VAS score rates the general state of health of a patient with 100 for the best imaginable health state and 0 for the worst imaginable health state.</description>
          <population>Full Analysis Population. The number of participants analyzed corresponds with number of subjects who completed the questionnaire in each treatment group.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="139"/>
                <count group_id="O3" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="1.43"/>
                    <measurement group_id="O2" value="2.6" spread="1.53"/>
                    <measurement group_id="O3" value="4.2" spread="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>dalfampridine-ER 5mg twice daily vs. placebo twice daily: Change from baseline in EQ-5D VAS score at Visit 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.055</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA model with change from baseline score as the dependant variable and baseline score and treatment as the independent variables.</method_desc>
            <param_type>Least Squares Mean</param_type>
            <param_value>-3.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.79</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.0</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>dalfampridine-ER 10mg twice daily vs. placebo twice daily: Change from baseline in EQ-5D VAS score at Visit 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.530</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA model with change from baseline score as the dependant variable and baseline score and treatment as the independent variables.</method_desc>
            <param_type>Least Squares Mean</param_type>
            <param_value>-1.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.83</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.7</ci_lower_limit>
            <ci_upper_limit>2.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>dalfampridine-ER 5mg twice daily vs. dalfampridine-ER 10mg twice daily: Change from baseline in EQ-5D VAS score at Visit 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.203</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA model with change from baseline score as the dependant variable and baseline score and treatment as the independent variables.</method_desc>
            <param_type>Least Squares Mean</param_type>
            <param_value>2.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.80</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.2</ci_lower_limit>
            <ci_upper_limit>5.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>On or after start of double-blind treatment through 14 days after the last dose for non-serious events, or up to 30 days after the last dose for serious adverse events (SAEs).</time_frame>
      <desc>Adverse events are treatment-emergent adverse events (TEAEs) that had a date of onset or worsening, on or after start of double-blind treatment. Number of participants exposed to study medication in the Dalfampridine-ER 10mg group (142) is 1 less than total # completed. 1 patient was randomized to Dalfampridine-ER 10mg but actually received placebo</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>placebo, twice daily</description>
        </group>
        <group group_id="E2">
          <title>Dalfampridine-ER 5mg</title>
          <description>5mg, twice daily
Dalfampridine-ER 5mg: 5mg, twice daily</description>
        </group>
        <group group_id="E3">
          <title>Dalfampridine-ER 10mg</title>
          <description>10mg, twice daily
Dalfampridine-ER 10mg: 10mg, twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Breast cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Ovarian adenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="80" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="84" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="143"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="144"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="144"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="143"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="144"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="143"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="144"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="143"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="144"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="143"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="144"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="143"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="144"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="144"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="143"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="144"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="143"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="144"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="143"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="144"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="143"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="144"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="143"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="144"/>
                <counts group_id="E3" events="17" subjects_affected="15" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="143"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="144"/>
                <counts group_id="E3" events="18" subjects_affected="18" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="143"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E3" events="12" subjects_affected="7" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="143"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="144"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor (Acorda) has right to review and comment on proposed publications within a specified time frame, up to 60 days; multi-center trials require joint publication unless specifically permitted otherwise.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice President - Clinical Development &amp; Medical Affairs</name_or_title>
      <organization>Acorda Therapeutics</organization>
      <phone>(914) 347- 4300 ext 5138</phone>
      <email>hhenney@acorda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

